Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Asset disposition
Inv. presentation
Acq. announced
Quarterly results
Auditor change
Appointed director
CC transcript
Director departure

SEELOS THERAPEUTICS, INC. (APRI) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/24/2019 GN Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
01/15/2019 GN Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.
12/14/2018 GN Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date
12/10/2018 GN Apricus Biosciences Reminds Shareholders to Vote Before the Special Meeting on December 14, 2018
07/30/2018 GN Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
05/03/2018 GN Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results
04/16/2018 GN Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
04/04/2018 GN Apricus Biosciences Announces Closing of $3.55 Million Public Offering
03/27/2018 GN Apricus Biosciences Announces Proposed Public Offering
03/26/2018 GN Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA
02/16/2018 GN Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
11/02/2017 GN Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
08/29/2017 GN Apricus Biosciences Files NDA Resubmission for Vitaros™
07/26/2017 GN Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
05/04/2017 GN Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
04/21/2017 GN Apricus Biosciences Announces Pricing of $7.0 Million Public Offering
03/13/2017 GN Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
02/09/2017 GN Apricus Biosciences Receives Positive Nasdaq Listing Determination
02/08/2017 GN Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
10/01/2012 GN Apricus Biosciences Announces Intent to File NDS for MycoVa(TM) in Canada
09/25/2012 GN Apricus Biosciences CEO to Present at Sachs Annual Biotech in Europe Investor Forum
09/17/2012 GN Apricus Biosciences Announces Publication in Journal of Pharmaceutics and Drug Delivery Research
08/22/2012 GN Apricus Biosciences' CEO to Present at the Stifel Nicolaus 2012 Healthcare Conference
08/20/2012 GN Apricus Biosciences Announces Podium Presentation of Vitaros(R) Clinical Data at 2012 World Meeting on Sexual Medicine

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy